Sold as Permax. Every FDA application for this active ingredient: 1 branded and 2 generic.
As of Nov 15, 2026, FDA lists 3 applications for Pergolide Mesylate (sold as Permax), first approved Dec 30, 1988, with 0 new uses approved and 0 published complete response letters.
| Dec 30, 1988 | PermaxNDA 19385 · New molecular entity | Valeant Pharm Intl | 30 | Discontinued |
| Nov 27, 2002 | Pergolide MesylateANDA 76061 | Strides Pharma | 1 | Discontinued |
| Sep 4, 2003 | Pergolide MesylateANDA 76094 | Ivax Sub Teva Pharms | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Strides Pharma